Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any acute myeloid leukemia that has the chromosomal anomaly FLT3 tyrosine kinase domain point mutation. (Single nucleotide mutations in the tyrosine kinase domain encoded by the human FLT3 gene that are associated with acute myeloid leukemia and poor prognosis.)
Biomarker and diagnostic research for acute myeloid leukemia, FLT3 tyrosine kinase domain point mutation has been reported in the published literature.
No clinical trials have been registered for acute myeloid leukemia, FLT3 tyrosine kinase domain point mutation.
9 publications have been identified in PubMed for acute myeloid leukemia, FLT3 tyrosine kinase domain point mutation. Research spans Basic Science / Preclinical (33%), Review / Meta-Analysis (22%), and Diagnostic / Biomarker (11%).
Afshari M (2026). [PMID: 41979996](https://pubmed.ncbi.nlm.nih.gov/41979996/). *Folia Biol (Praha)*. [Review / Meta-Analysis]
Nakao F (2026). [PMID: 42104002](https://pubmed.ncbi.nlm.nih.gov/42104002/). *Ann Hematol*. [Case Report / Case Series]
Chen YJ (2025). [PMID: 39885312](https://pubmed.ncbi.nlm.nih.gov/39885312/). *Acta Pharmacol Sin*. [Basic Science / Preclinical]
Younus S (2025). [PMID: 41215958](https://pubmed.ncbi.nlm.nih.gov/41215958/). *Comput Struct Biotechnol J*. [Basic Science / Preclinical]
Anabtawi N (2025). [PMID: 39806020](https://pubmed.ncbi.nlm.nih.gov/39806020/). *Leukemia*. [Diagnostic / Biomarker]
Data assembled from 2 of 12 sources · Last updated Sep 20, 2026, 9:48 PM UTC
Common questions about acute myeloid leukemia, FLT3 tyrosine kinase domain point mutation
Fujii-Hanamoto A (2025). [PMID: 41150745](https://pubmed.ncbi.nlm.nih.gov/41150745/). *Curr Issues Mol Biol*. [Basic Science / Preclinical]
Matsukawa T (2024). [PMID: 39614924](https://pubmed.ncbi.nlm.nih.gov/39614924/). *Ann Hematol*. [Clinical Trial Publication]
Macečková D (2024). [PMID: 38625438](https://pubmed.ncbi.nlm.nih.gov/38625438/). *Mol Biol Rep*. [Review / Meta-Analysis]
Alreemi RM (2024). [PMID: 39132250](https://pubmed.ncbi.nlm.nih.gov/39132250/). *Bioinformation*. [Gene Therapy / Novel Therapeutics]